TP53 and malignant colon neoplasm: SIRT1 as a therapeutic target in tumourigenesis has been ground for debates on two conflicting, dichotomic thesis, which postulated its deacetylase enzymatic activity as pro- or anti-oncogenic.44 The link of NSAIDs with the SIRT1/p53 pathway was raised also by other groups reporting the pro-senescence effects of aspirin in breast25 and colon cancer cell lines,45 although a direct effect of aspirin on SIRT1 activity has never been demonstrated.